Hyderabad-Based Biotech to Produce 200 Million Sputnik V Vaccines Annually

The Russian Direct Investment Fund (RDIF) and Virchow Biotech Private Limited, one of the leading manufacturers of vaccines and pharmaceuticals in India, announced an agreement to manufacture in India up to 200 million doses of the Sputnik V vaccine annually.

Completing the technology transfer is planned for the 2nd quarter of 2021, when the full-scale production of the Sputnik V vaccine will be launched.

Dr. Tummuru Murali, Managing Director of Virchow Biotech, commented in a press release, “Virchow’s proven capabilities in large-scale drug substance manufacturing should help meet the global demand for this vaccine. We are also happy to learn of the positive feedback that this vaccine has been receiving from all сountries.”

Hyderabad-based Virchow Biotech Private Limited is part of the Virchow Group, which has an operational experience of over 4 decades has a global footprint in over 100 countries, supporting about 3,500 employees with an annual turnover of over $600 million. 

The Sputnik V vaccine has been approved in 55 countries with a total population of over 1.4 billion people, says the RDIF. The Sputnik V (Gam-COVID-Vac) vaccine reduces the time taken for the actual development of immunity to SARS-CoV-2, the virus behind the COVID-19 pandemic.